ISSN : 0376-4672
비스포스포네이트 관련 악골 괴사(Bisophosphonate Related Osteonecrosis of Jaws,BRONJ)는 2003년 Marx에 의하여 처음으로 보고되었고 이후 이 질환과 관련된 보고가 점차 늘어나고있다. 비스포스포네이트 재제는 파골 세포를 억제하는 기전을 통해 골다공증 치료제로서 광범위하게 사용되고 있으며 그 외 파젯병, 다발성 골수종, 고칼슘혈증, 뼈로 전이된 악성종양에서 사용되고 있다. BRONJ 는 비스포스포네이트를 장기간 경구 혹은주사로 투여 받은 환자에서 발생 위험성이 높으며 발치와 같은 외과적 치료 후 골 치유가 지연되고 구강내 골 노출 및 괴사, 통증, 치은 부종, 감염, 농양, 누공 형성 등의 임상적 특징을 나타낸다. 미국 구강악안면외과학회(AAOMS)는 BRONJ를 비스포스포네이트를 투여 받고 있거나 투여 받았으며 악안면 영역에 방사선 치료를 받지 않은 환자 중 8 주 이내에 치유되지 않고 노출된 악안면 골조직을 가진 경우로 정의하였다.
1. Burchardt H. The biology of bone graft repair. Clinical orthopaedics and related research 1983:28.
2. Jeon S, Chae J, Lee E. Recent research trends of bone graft. Tissue Eng Regen Med 2008;5:791.
3. Urist M, Dowell T, Hay P, Strates B. Inductive substrates for bone formation. Clinical orthopaedics and related research 1968;59:59.
4. Nyströom E, Legrell P, Forssell, Kahnberg K. Combined use of bone grafts and implants in the severely resorbed maxilla Postoperative evaluation by computed tomography. International Journal of Oral & Maxillofacial Surgery 1995;24:20.
5. Choi J, Shin H. Requirements of artificial materials for alveolar bone regeneration. Tissue Eng Regen Med 2007;4:478.
6. Yun S, Kim Y, Kwon O. Fabrication and characterization of biodegradable nanofiber containing gelatin. Tissue Eng Regen Med 2008;5:835.
7. Friedlaender G. Osteogenic protein-1 in treatment of tibial nonunions: current status. Surg technol int 2004;13:249-52
8. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2008;2:81-96
9. Kanakaris NK, Giannoudis PV. Clinical applications of bone morphogenetic proteins: current evidence. J Surg Orthop Adv 2008;17:133-46
10. Mont MA, Ragland PS, Biggins B, Friedlaender G, Patel T, Cook S, Etienne G, Shimmin A, Kildey R, Rueger DC. Use of bone morphogenetic proteins for musculoskeletal applications: an overview. J Bone Joint Surg Am 2004;86: 41-55
11. Takahashi Y, Yamamoto M, Tabata Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and β-tricalcium phosphate. Biomaterials 2005;26:4856-65
12. Carter TG, Brar PS, Tolas A, Beirne OR. Off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for reconstruction of mandibular bone defects in humans. J Oral Maxillofac Surg 2008;66:1417-25.
13. Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, Harpring J, Shields CB. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006;31: 542-7.
14. Hoexter D. Bone regeneration graft materials. Journal of Oral Implantology. 2002;28:290.
15. Patel ZS, Young S, Tabata Y, Jansen JA, Wong MEK, Mikos AG. Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone 2008;43:931-40.
16. La WG, Kang SW, Yang HS, Bhang SH, Lee SH, Park JH, Kim BS. The efficacy of bone morphogenetic protein-2 depends on its mode of delivery. Artif Organs 2010;34: 1150-3.
17. Liu HW, Chen CH, Tsai CL, Hsiue GH. Targeted delivery vehicle for juxtacrine signaling growth factor based on rhBMP-2-mediated carrier-protein conjugation. Bone 2006; 39:825-36.
18. Uludag H, D'Augusta D, Palmer R, Timony G, Wozney J. Characterization of rhBMP 2pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res 1999;46:193-202.
19. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: current challenges in BMP delivery. Biotechnol Lett 2009;31:1817-24.
20. Zhao B, Katagiri T, Toyoda H, Takada T, Yanai T, Fukuda T, Chung UI, Koike T, Takaoka K, Kamijo R. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 2006;281:23246-53.
21. Friberg O. Local collagen-entamicin for prevention of sternal wound infections: the LOGIP trial. Apmis. 2007;115:1016?1.
22. Jensen T, Rahbek O, Overgaard S, S?alle K. No effect of platelet-rich plasma with frozen or processed bone allograft around noncemented implants. International orthopaedics 2005;29:67.
23. Linde A, Thoren C, Dahlin C, Sandberg E. Creation of new bone by an osteopromotive membrane technique: an experimental study in rats. Journal of Oral and Maxillofacial Surgery 1993;51:892.
24. Byne EM, Farrel E, McMahon LA, Haugh MG, O'Brien FJ, Campbell VA, Prendergast PJ. &O'Connell, BC. Gene expression by marrow stromal cells in a porous collagenglycosaminoglycan scaffold is affected by pore size and mechanical stimulation, J Mat Sci Mat Med 19:3455.
25. Boerckel JD, Kolambkar YM, Dupont KM, Uhrig BA, Phelps EA, Stevens HY, Garc?a AJ, Guldberg RE. Effects of protein dose and delivery vehicle on BMP-mediated bone regeneration. Biomaterials 2011;32:5241-51
26. Fu YC, Nie H, Ho ML, Wang CK, Wang CH. Optimized bone regeneration based on sustained release from three dimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2. Biotechnol Bioeng 2008;99:996-1006
27. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: current challenges in BMP delivery. Biotechnol Lett 2009;31:1817-24
28. Dayisoylu EH, ¸senel Fç, üngör C, Tosun E, çankaya M, Ersöz S, Taskesen F. The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws:an animal study. Int J Oral Maxillofac Surg 2013Nov;42(11):1475-80
29. Marco Mozzati, Giorgia Gallesio, Valentina Arata, Renato Pol, Matteo Scoletta. Platelet-rich therapies in the treatment of intraveonus bisphosphonate-related osteonecrosis of the jaw:A report of 32 cases. Oral oncology 48(2012):469-474
30. Curi MM1, Cossolin GS, Koga DH, Araújo SR, Feher O, dos Santos MO, Zardetto C. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3cases. J Oral Maxillofac Surg. 2007Feb;65(2):349-55.
31. Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol. 2007;33(6):371-82
32. Adornato MC1, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc. 2007 Jul;138(7):971-7.
33. Bocanegra-Pérez S1, Vicente-Barrero M, Knezevic M, Castellano-Navarro JM, Rodríguez-Bocanegra E, Rodríguez-Millares J, Pérez-Plasencia D, Ramos-Macías A. Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2012 Nov;41(11):1410-5
34. Coleman RE. Bisohosphonate: clinical experience. Oncologist 2004;9(4):14-27
35. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a longterm complication of bisphosphonate treatment. Lancet oncol 2006;7:508-14
36. Scoletta M, Arduino PG, Dalmasso P, Broccoletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaw: a prospective study. Oral Surg Oral med Oral Pathol Oral Radiol Endod 2010;110:46-53
37. Molina-Minano F, Lopez-Jronet P, Camacho-Alonso F, Vicente-ortega V. Plasma rich in growth factors and bone formation: a radiological and histomorphometric study in New Zealand rabbits. Braz Oral Res 2009;23:275-80
38. Marx R. Oral and intravenous bisphosphonateinduced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Hanover Park, I.L:Quintessence Publishing Co., Inc.; 2007
39. Graziani F, Cei S, La Ferla F, Cerri E, Itro A, Gabriele M. Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy. J Craniofac Surg. 2006Sep;17(5):876-9.
40. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med. 2007 Jul;36(6):319-28.
41. Magopoulos C1, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, Delaroudis S. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol. 2007 May-Jun;28(3):158-63.
42. Wutzl A1, Biedermann E, Wanschitz F, Seemann R, Klug C, Baumann A, Watzinger F, Schicho K, Ewers R, Millesi G. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2008 Sep;30(9):1224-30. 3
43. Montebugnoli L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, Marchetti C. Biphosphonateassociated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007Oct;104(4):473-7.
44. Goto H, Matsuyama T, Miyamoto M, Yonamine Y, Izumi Y. Platelet-rich plasma/osteoblasts complex induces bone formation via osteoblastic differentiation following subcutaneous transplanta tion. J Periodontal Res. 2006 Oct;41(5):455-62
45. Badr MS, Oliver RJ. Platelet-rich plasma: an adjunctive treatment modality for bisphosphonate osteonecrosis? J Oral Maxillofac Surg. 2009Jun;67(6):1357.
46. Dehari H, Tomihara K, Ueda M, Shimanishi M, Ono M, Sasaki T, Igarashi T, Shiratori K, Abe M, Ogi K, Nakamori K, Miyazaki A, Nagai I, Hiratsuka H. Clinical investigation of bisphosphonate-related osteonecrosis of the jaws. Gan To Kagaku Ryoho. 2009 Dec;36(13):2587-92.
47. Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol. 2010Apr;59(4):181-203, 204-13
48. Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY.Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int. 2012Nov;23(11):2721-5
49. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws:clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg. 2009May;67(5 Suppl):35-43.
50. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 May;67(5Suppl):44-52.
